It's either Pfizer because it's main cancer drug is going off patent in a few years or someone who sees potential in a drug not targeting surface antigen markers which is old IP . Cell nucleus penetrative antibodies are the new potential in cancer treatment. Novel and unique we are.
It's either Pfizer because it's main cancer drug is going off...
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $14.40M | |||
| Open | High | Low | Value | Volume |
| 0.7¢ | 0.7¢ | 0.7¢ | $20 | 2.851K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 23 | 7843182 | 0.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.8¢ | 3015083 | 4 |
View Market Depth
| Last trade - 10.06am 06/06/2024 (20 minute delay) ? |
|
|||||
|
Last
0.7¢ |
Change
0.000 ( 0.00 %) |
||||
| Open | High | Low | Volume | ||
| 0.8¢ | 0.8¢ | 0.7¢ | 223170 | ||
| Last updated 13.08pm 06/06/2024 ? | |||||
| PAB (ASX) Chart |